Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.

doi:10.1038/s41467-024-50056-y

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.

Nature communications - 11 Jul 2024

Brasó-Maristany Fara, Ferrero-Cafiero Juan Manuel, Falato Claudette, Martínez-Sáez Olga, Cejalvo Juan Miguel, Margelí Mireia, Tolosa Pablo, Salvador-Bofill Francisco Javier, Cruz Josefina, González-Farré Blanca, Sanfeliu Esther, Òdena Andreu, Serra Violeta, Pardo Francisco, Luna Barrera Ana María, Arumi Miriam, Guerra Juan Antonio, Villacampa Guillermo, Sánchez-Bayona Rodrigo, Ciruelos Eva, Espinosa-Bravo Martín, Izarzugaza Yann, Galván Patricia, Matito Judith, Pernas Sonia, Vidal Maria, Santhanagopal Anu, Sellami Dalila, Esker Stephen, Fan Pang-Dian, Suto Fumitaka, Vivancos Ana, Pascual Tomás, Prat Aleix, Oliveira Mafalda

Abstract excerpt

Patritumab deruxtecan (HER3-DXd) exhibits promising efficacy in breast cancer, with its activity not directly correlated to baseline ERBB3/HER3 levels. This research investigates the genetic factors affecting HER3-DXd's response in women with early-stage hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer. In the SOLTI-1805 TOT-HER3 trial, a single HER3-DXd dose was administered to 98 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal

Share to Antibodies, Monoclonal, Humanized

Share to Broadly Neutralizing Antibodies

Share to Camptothecin

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Immunoconjugates

Share to Receptor, ErbB-3

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 38992028
DOI: 10.1038/s41467-024-50056-y
PMCID: PMC11239918

Genes

ERBB2
CCNE1
ERBB3
MKI67
NAT1
SLC39A6
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.PMID 38992028Read ↗

Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational statusSemantic proximity Read ↗

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression.Semantic proximity Read ↗

Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.Semantic proximity Read ↗

Mechanism of action and resistance to Trastuzumab Deruxtecan in patients with metastatic breast cancer: the DAISY trialSemantic proximity Read ↗

Real-world activity of trastuzumab deruxtecan in heavily pretreated HER2-expressing ovarian cancer: focusing on HER2-low responses and <i>CCNE1</i> amplificationSemantic proximity Read ↗

Dissecting the biological heterogeneity of HER2-positive breast cancerSemantic proximity Read ↗

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.Semantic proximity Read ↗

340O Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC)Semantic proximity Read ↗

Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancerSemantic proximity Read ↗

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III TrialSemantic proximity Read ↗

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.